Acorda Therapeutics
Acorda Therapeutics posts net loss of $0.15 per share
Published in Healthcare Finance, Tax and Law Weekly, August 30th, 2006
For the quarter ended June 30, 2006, gross sales were $3.9 million for Zanaflex Capsules (tizanidine hydrochloride) and $4.0 million for Zanaflex (tizanidine hydrochloride) tablets. For the same quarter in 2005 we recognized gross sales of Zanaflex Capsules of $311,000 and gross sales of Zanaflex tablets of $167,000. Gross sales are recognized using a deferred revenue recognition model, where product shipments to wholesalers are recorded as deferred revenue, and later recognized as gross sales when end-user prescriptions are reported.
During the quarter...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Abraxis BioScience
Abraxis BioScience reports earnings per share of $0.17 - Acceleron Pharma
Acceleron Pharma closes $30 million series B financing - Acura Pharmaceuticals
Acura Pharmaceuticals reports loss of $0.01 per share - Adolor
Adolor reports loss of $0.35 per share - Advanced Medical Optics
Advanced Medical Optics posts 13.2% increase in sales - Advancis Pharmaceutical
Advancis Pharmaceutical reports net loss of $0.35 per share - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
